New Drug Approvals

SYDNEY and BEDMINSTER, N.J., March 14, 2013

QRxPharma Limited announced today the US Food and Drug Administration (FDA) has set 26 August 2013 as the Prescription Drug User Fee Act (PDUFA) date for action on the Company’s resubmitted MoxDuo New Drug Application (NDA).

“We are pleased that the FDA has formally accepted our resubmitted MoxDuo NDA” said Dr. John Holaday , Managing Director and Chief Executive Officer, QRxPharma. “We expect the Advisory Committee meeting to be scheduled between late June and late July and will update shareholders once formal notification has been received,” added Holaday.

The NDA is the basis for recommencing the regulatory approval process for MoxDuo for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the US. MoxDuo, an immediate release Dual Opioid® pain therapy, is a patented 3:2 fixed ratio combination of…

View original post 15 more words


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s